Mar 23 |
Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway
|
Mar 21 |
Cabaletta Bio files automatic mixed securities shelf
|
Mar 21 |
Cabaletta Bio GAAP EPS of -$0.46
|
Mar 21 |
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Mar 20 |
Cabaletta gets FDA orphan drug status for systemic sclerosis drug
|
Mar 20 |
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
|
Mar 8 |
Jim Cramer’s 10 Latest Stock Picks This Week
|
Mar 6 |
Cramer: This REIT Is 'A Little Too Dicey'; As For Marathon Digital, 'Own The Pure'
|
Feb 27 |
Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4
|
Feb 27 |
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
|